Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rocket Pharmaceuticals Inc (NQ: RCKT )

11.74 -0.18 (-1.51%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rocket Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 Next >
Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Rocket Pharmaceuticals, Inc.
Via Business Wire
3 Small-Cap Stocks That Are Ready to Rocket Higher
With lower interest rates and lower corporate taxes more likely, it's a good time to consider three small-cap stocks that present a buying opportunity 
Via MarketBeat
Topics Government
Exposures Political
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst
Rocket Pharmaceuticals reveals RP-A501 Phase 1 data for Danon disease, showing durable efficacy, reduced cardiac biomarkers, and improved heart health. 
Via Benzinga
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association’s 2024 Late-Breaking Science Sessions
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
Via Benzinga
RCKT Stock Earnings: Rocket Pharmaceuticals Misses EPS for Q2 2024
RCKT stock results show that Rocket Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides
Rocket Pharmaceuticals shares fell after the FDA issued a Complete Response Letter for Kresladi, a gene therapy for severe leukocyte adhesion deficiency-I. The FDA requested additional CMC... 
Via Benzinga
Exposures Product Safety
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains
These biotech stocks, lacking in profitability but seeding huge potential, should be on your watchlist. 
Via Talk Markets
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
RCKT Stock Earnings: Rocket Pharmaceuticals Beats EPS for Q1 2024
RCKT stock results show that Rocket Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
7 Speculative Stocks to Double Your Money THIS Year
Although terribly risky, these stocks to double your money could be enticing if you have some pocket change lying around. 
Via InvestorPlace
Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
From Rocket Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.